This document discusses the use of the Prolaris test in decision making for prostate cancer treatment. It describes several case studies where Prolaris provided more precise risk stratification compared to standard tests like Gleason score and CAPRA. Prolaris separated patients into more meaningful low and high risk groups, changing treatment decisions in about 2/3 of cases. The document argues Prolaris adds value by improving risk prediction compared to existing tools. It suggests Prolaris could be incorporated into optimal prostate cancer care pathways to better guide active surveillance versus immediate treatment.
The document summarizes key statistics from the American Cancer Society's Facts & Figures 2013 report. It states that cancer is the second leading cause of death in the US, with over 1.6 million new cases expected in 2013. The most common cancers are prostate cancer in men (28% of cases) and breast cancer in women (29% of cases). Lung cancer causes the most cancer deaths. It also provides details on prostate, breast and lung cancer cases and survival rates.
Pros and cons of prostate cancer screening by mungai ngugiKesho Conference
1) Prostate cancer screening can have both benefits and harms. The benefits include reducing mortality from prostate cancer by detecting it at an early stage, but screening also commonly results in false positives.
2) Common harms of screening include overdiagnosis where cancers are detected that would never have caused harm, false positives which can lead to invasive biopsies, and potential complications from treatment of screen-detected cancers including incontinence and erectile dysfunction.
3) Guidelines from organizations disagree on screening recommendations for men of different ages, but shared decision making is encouraged to weigh the benefits and harms based on individual risk factors and preferences.
What are the problems with transrectal biopsies of the prostate for prostate ...Marc Laniado
Transrectal prostate biopsies carry risks of infection in 1-4% of men and can underestimate or miss cancers at the front of the prostate. Unguided biopsies may incorrectly interpret a small cancer as more significant or fail to fully represent an important cancer. An ideal biopsy would accurately target cancers without risk of infection.
Prostate cancer - Vincent Batista LemaireNiela Valdez
The document summarizes the PI-RADS (Prostate Imaging Reporting and Data System) guidelines for prostate imaging and reporting. It describes the goal of PI-RADS to standardize acquisition, interpretation, and reporting of prostate imaging globally. It also reviews techniques for prostate cancer screening and diagnosis including digital rectal exam, prostate-specific antigen testing, transrectal ultrasound biopsy, and multiparametric magnetic resonance imaging, and discusses the Gleason grading system for evaluating prostate cancer specimens.
1) A study called PIVOT compared radical prostatectomy to observation in men with early stage prostate cancer over 12 years and found no significant difference in mortality. An extended follow up of PIVOT over 20 years still found no significant difference in all-cause or prostate cancer mortality between the two groups.
2) Absolute differences in mortality risk increased slightly over time but remained small, with less than a 6 percentage point difference in all-cause mortality and 4 percentage points for prostate cancer mortality. Surgery was associated with less disease progression but most progression was asymptomatic.
3) The study concludes that radical prostatectomy was not associated with significantly lower mortality compared to observation over 20 years. Death from prostate cancer was very uncommon
Prostate cancer is one of the most common cancers in American men. The document discusses risk factors for prostate cancer such as age, family history, diet, weight, and provides tips for prevention including eating a healthy diet, exercising, maintaining a healthy weight, and avoiding smoking. It also provides statistics on prostate cancer prevalence, risk reduction strategies, and introduces Columbus CyberKnife as a nonsurgical treatment option using radiosurgery.
Mills-Peninsula Health Services 2013 Cancer Symposium presentation - Brad Ekstrand, MD/PhD, California Cancer Care Mills-Peninsula Health Services San Mateo, CA
This document discusses the use of the Prolaris test in decision making for prostate cancer treatment. It describes several case studies where Prolaris provided more precise risk stratification compared to standard tests like Gleason score and CAPRA. Prolaris separated patients into more meaningful low and high risk groups, changing treatment decisions in about 2/3 of cases. The document argues Prolaris adds value by improving risk prediction compared to existing tools. It suggests Prolaris could be incorporated into optimal prostate cancer care pathways to better guide active surveillance versus immediate treatment.
The document summarizes key statistics from the American Cancer Society's Facts & Figures 2013 report. It states that cancer is the second leading cause of death in the US, with over 1.6 million new cases expected in 2013. The most common cancers are prostate cancer in men (28% of cases) and breast cancer in women (29% of cases). Lung cancer causes the most cancer deaths. It also provides details on prostate, breast and lung cancer cases and survival rates.
Pros and cons of prostate cancer screening by mungai ngugiKesho Conference
1) Prostate cancer screening can have both benefits and harms. The benefits include reducing mortality from prostate cancer by detecting it at an early stage, but screening also commonly results in false positives.
2) Common harms of screening include overdiagnosis where cancers are detected that would never have caused harm, false positives which can lead to invasive biopsies, and potential complications from treatment of screen-detected cancers including incontinence and erectile dysfunction.
3) Guidelines from organizations disagree on screening recommendations for men of different ages, but shared decision making is encouraged to weigh the benefits and harms based on individual risk factors and preferences.
What are the problems with transrectal biopsies of the prostate for prostate ...Marc Laniado
Transrectal prostate biopsies carry risks of infection in 1-4% of men and can underestimate or miss cancers at the front of the prostate. Unguided biopsies may incorrectly interpret a small cancer as more significant or fail to fully represent an important cancer. An ideal biopsy would accurately target cancers without risk of infection.
Prostate cancer - Vincent Batista LemaireNiela Valdez
The document summarizes the PI-RADS (Prostate Imaging Reporting and Data System) guidelines for prostate imaging and reporting. It describes the goal of PI-RADS to standardize acquisition, interpretation, and reporting of prostate imaging globally. It also reviews techniques for prostate cancer screening and diagnosis including digital rectal exam, prostate-specific antigen testing, transrectal ultrasound biopsy, and multiparametric magnetic resonance imaging, and discusses the Gleason grading system for evaluating prostate cancer specimens.
1) A study called PIVOT compared radical prostatectomy to observation in men with early stage prostate cancer over 12 years and found no significant difference in mortality. An extended follow up of PIVOT over 20 years still found no significant difference in all-cause or prostate cancer mortality between the two groups.
2) Absolute differences in mortality risk increased slightly over time but remained small, with less than a 6 percentage point difference in all-cause mortality and 4 percentage points for prostate cancer mortality. Surgery was associated with less disease progression but most progression was asymptomatic.
3) The study concludes that radical prostatectomy was not associated with significantly lower mortality compared to observation over 20 years. Death from prostate cancer was very uncommon
Prostate cancer is one of the most common cancers in American men. The document discusses risk factors for prostate cancer such as age, family history, diet, weight, and provides tips for prevention including eating a healthy diet, exercising, maintaining a healthy weight, and avoiding smoking. It also provides statistics on prostate cancer prevalence, risk reduction strategies, and introduces Columbus CyberKnife as a nonsurgical treatment option using radiosurgery.
Mills-Peninsula Health Services 2013 Cancer Symposium presentation - Brad Ekstrand, MD/PhD, California Cancer Care Mills-Peninsula Health Services San Mateo, CA
Screening for Prostate cancer has had many different opinions and much research has been conducted in the last 20 years. In this presentation we will discuss the current guidelines for proper screening and gain more insight into men’s health.
Prostate cancer detection, UroLifts, HaematuriaMarc Laniado
This document discusses innovations in prostate disease management, including focal therapy options for prostate cancer and the UroLift procedure for treating benign prostatic hyperplasia (BPH). It summarizes guidelines for investigating hematuria and evaluating prostate cancer risk. It also compares treatment options for localized prostate cancer and BPH, noting UroLift offers symptom relief while preserving sexual function unlike other BPH treatments. Clinical data shows UroLift improves urinary symptoms and quality of life compared to TURP, with faster recovery and no effect on ejaculation.
Screening for prostate cancer using PSA has several limitations. It It is an organ specific marker, however, pathology specificity is low (elevated in all, prostatitis, prostatomegaly, prostate cancer, prostate manipulation). Attempts have been made to improve specificity while retaining its sensitivity, e.g. PSA density, PSA % free, PSA velocity, prostate health index (which takes into account p2PSA as well).
after diagnosis of prostate cancer, PSA doubling time is used for assessment of indication of treatment for patients on active surveillance as well as that for indication of salvage treatment for patients with biochemical recurrence after initial treatment.
1) The accuracy of the PSA test for detecting prostate cancer depends on the age of the patient and the prevalence of prostate cancer, which increases significantly with age.
2) For patients under 70 years old, the PSA test has very low accuracy, ranging from near 0% to 22% accuracy, which could lead to many unnecessary invasive biopsies.
3) The U.S. Preventive Services Task Force recommends against PSA-based prostate cancer screening for men 75 and older, and makes no recommendation for men under 75 due to inadequate evidence that screening improves health outcomes.
Prostate cancer is a relatively common cancer in men over 60. If not treated early, it can spread from the prostate to bones and lymph nodes. Symptoms may include bone pain, urinary problems, erectile dysfunction, pelvic discomfort, and weak urine stream. Services offered to treat prostate cancer include radiation therapy, hormonal treatment, surgical removal of the testicles or prostate gland, and transurethral resection of the prostate. Men experiencing symptoms should book an appointment with a urologist.
Screening for prostate cancer remains controversial due to the high risk of overdiagnosis and overtreatment. While screening can find early-stage cancers, most prostate cancers grow slowly and will not cause harm. Screening often leads to unnecessary biopsies, treatments and side effects like impotence and incontinence without clear benefits. Younger, low-risk men are unlikely to benefit from PSA screening, while older men or those at higher risk may benefit if screening finds aggressive cancers early. Active surveillance is often preferred over immediate treatment for low-risk prostate cancers found by screening. Overall, more research is still needed to determine which men would benefit most from prostate cancer screening.
The document summarizes the key findings and implications of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). The trial found that for men with low-risk prostate cancer, radical prostatectomy did not provide a benefit over observation in reducing mortality rates. This suggests that observation may be a reasonable option for some low-risk prostate cancer patients over age 60. However, the trial also implied that radical prostatectomy may provide survival benefits for those with higher-risk disease. The document discusses several limitations of the PIVOT trial and ongoing debates around the management and treatment of localized prostate cancer.
Philadelphia CyberKnife presents the American Cancer Society Facts and Figures 2013 annual report outlining the estimated numbers of new cancer cases and deaths in 2013 as well as current cancer incidence, mortality, and survival statistics and information on cancer symptoms, risk factors, early detection and treatment.
Prostate cancer - diagnosis using prostate cancer risk calculators, multiparametric MRI, MRI-targeted transperineal prostate biopsies using software registration
About 50% of all men by 50years will have prostate cancer cells at the dormant stage in their prostate gland so the question now is why are there great geographical prostate cancer variations? It is also believed men of Africa descent have high androgen level than white men and is the fuel for prostate cancer. According to a publication by the Ghana news Agency, Ghana has exceeded the global prostate limits as the country records 200 cases out of every 100,000 men as against 170 world-wide, a survey by the Korle -Bu Teaching Hospital revealed(GNA - August, 07, 2007). This study aims to look at the impact of alternative medicine on Ghanaian men of African descent diagnosed with prostate cancer. This research study is in two forms, firstly an observational study will be used to assess Ghanaian men diagnosed with Prostate cancer and the use of traditional medicinal plant call croton membranaceus to ascertain its anti cancer efficacy. Croton membranaceus root extract marketed as URO 500 at Center For Plant Medicine Research in Ghana (Mampong , Akuapem) 10mg per capsule will be given to about 30 patient diagnosed with Prostate Cancer at the experimental site , De Men’s Clinic & Prostate Research Lab in Dodowa, Akoto House for an observational study to be conducted and cohort for this important research will report after three month of treatment after which their PSA will be assess again as the PSA is the best marker in terms of the diseases monitoring or progressing.
Secondly, an extensive research using online search engines to conduct a literature review, summarizing the body of evidence on impact of alternative medicine and prostate cancer use in men of African descent to date will be use for this important second phase of the study.
Results will be analyzed using the PSA at the stage at diagnosis and after treatment with the croton membranous. The International Prostate Symptoms score (IPSS) and the international Index of Erectile Function (IIEF) questionnaire will also be assessing before and after. Abdominopelvic Scan using Sonoscape A6 with full bladder to enable acoustic widow to assess prostate Volume before and after will also be access.
Evolving recommendations in prostate cancer screeningsummer elmorshidy
Prostate cancer screening recommendations have evolved as more evidence has emerged. Early approaches recommended annual PSA screening for all men over 50, but two large trials had conflicting results. One found no mortality benefit, while the other found a 21% reduction in men aged 55-69. However, significant overdiagnosis and harms were recognized, including false positives in 75% of biopsied men. Current guidelines recommend shared decision making for screening in men 55-69 and against screening for other age groups. Improved tests are still needed to better distinguish indolent from aggressive cancers.
This document discusses cancer screening guidelines for several common cancers. It recommends screening for breast cancer with annual mammograms and clinical exams starting at age 40, and beginning earlier or including MRI for those at high risk. Cervical cancer screening should begin at age 21 with Pap tests every 3 years or co-testing with HPV every 5 years. Colorectal cancer screening options include colonoscopy every 10 years, sigmoidoscopy every 5 years, or annual fecal tests. Genetic screening is recommended for those with a family history suggesting inherited cancer risk. Lung cancer screening with low-dose CT is advised for high-risk smokers aged 55-74. Prostate cancer screening involves PSA testing and DRE for men aged 50-69
Bitsie, K. (2015). Cancer Risk and Cancer Screening in a Pacific Northwest TribeNatalie Chin
This study assessed cancer risk factors and screening in the Cow Creek Band of Umpqua Tribe in Oregon through a survey of 283 tribal members. Compared to non-Hispanic whites in Oregon, tribal members were more likely to be obese and current smokers but had similar or higher rates of cancer screening. Specifically, tribal members were more likely to have received fecal occult blood tests and clinical breast exams recently. While some risk factors were elevated, cancer screening rates were generally favorable and suggested the tribe's health programs were having a positive impact.
Rush Radiosurgery presents the American Cancer Society Facts and Figures 2013 annual report outlining the estimated numbers of new cancer cases and deaths in 2013 as well as current cancer incidence, mortality, and survival statistics and information on cancer symptoms, risk factors, early detection, and treatment.
Lung Cancer is the leading cause of cancer-related deaths in the United States. Learn more about lung tumors and how Louisville CyberKnife's noninvasive treatment may be right for you.
Screening for Prostate cancer has had many different opinions and much research has been conducted in the last 20 years. In this presentation we will discuss the current guidelines for proper screening and gain more insight into men’s health.
Prostate cancer detection, UroLifts, HaematuriaMarc Laniado
This document discusses innovations in prostate disease management, including focal therapy options for prostate cancer and the UroLift procedure for treating benign prostatic hyperplasia (BPH). It summarizes guidelines for investigating hematuria and evaluating prostate cancer risk. It also compares treatment options for localized prostate cancer and BPH, noting UroLift offers symptom relief while preserving sexual function unlike other BPH treatments. Clinical data shows UroLift improves urinary symptoms and quality of life compared to TURP, with faster recovery and no effect on ejaculation.
Screening for prostate cancer using PSA has several limitations. It It is an organ specific marker, however, pathology specificity is low (elevated in all, prostatitis, prostatomegaly, prostate cancer, prostate manipulation). Attempts have been made to improve specificity while retaining its sensitivity, e.g. PSA density, PSA % free, PSA velocity, prostate health index (which takes into account p2PSA as well).
after diagnosis of prostate cancer, PSA doubling time is used for assessment of indication of treatment for patients on active surveillance as well as that for indication of salvage treatment for patients with biochemical recurrence after initial treatment.
1) The accuracy of the PSA test for detecting prostate cancer depends on the age of the patient and the prevalence of prostate cancer, which increases significantly with age.
2) For patients under 70 years old, the PSA test has very low accuracy, ranging from near 0% to 22% accuracy, which could lead to many unnecessary invasive biopsies.
3) The U.S. Preventive Services Task Force recommends against PSA-based prostate cancer screening for men 75 and older, and makes no recommendation for men under 75 due to inadequate evidence that screening improves health outcomes.
Prostate cancer is a relatively common cancer in men over 60. If not treated early, it can spread from the prostate to bones and lymph nodes. Symptoms may include bone pain, urinary problems, erectile dysfunction, pelvic discomfort, and weak urine stream. Services offered to treat prostate cancer include radiation therapy, hormonal treatment, surgical removal of the testicles or prostate gland, and transurethral resection of the prostate. Men experiencing symptoms should book an appointment with a urologist.
Screening for prostate cancer remains controversial due to the high risk of overdiagnosis and overtreatment. While screening can find early-stage cancers, most prostate cancers grow slowly and will not cause harm. Screening often leads to unnecessary biopsies, treatments and side effects like impotence and incontinence without clear benefits. Younger, low-risk men are unlikely to benefit from PSA screening, while older men or those at higher risk may benefit if screening finds aggressive cancers early. Active surveillance is often preferred over immediate treatment for low-risk prostate cancers found by screening. Overall, more research is still needed to determine which men would benefit most from prostate cancer screening.
The document summarizes the key findings and implications of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). The trial found that for men with low-risk prostate cancer, radical prostatectomy did not provide a benefit over observation in reducing mortality rates. This suggests that observation may be a reasonable option for some low-risk prostate cancer patients over age 60. However, the trial also implied that radical prostatectomy may provide survival benefits for those with higher-risk disease. The document discusses several limitations of the PIVOT trial and ongoing debates around the management and treatment of localized prostate cancer.
Philadelphia CyberKnife presents the American Cancer Society Facts and Figures 2013 annual report outlining the estimated numbers of new cancer cases and deaths in 2013 as well as current cancer incidence, mortality, and survival statistics and information on cancer symptoms, risk factors, early detection and treatment.
Prostate cancer - diagnosis using prostate cancer risk calculators, multiparametric MRI, MRI-targeted transperineal prostate biopsies using software registration
About 50% of all men by 50years will have prostate cancer cells at the dormant stage in their prostate gland so the question now is why are there great geographical prostate cancer variations? It is also believed men of Africa descent have high androgen level than white men and is the fuel for prostate cancer. According to a publication by the Ghana news Agency, Ghana has exceeded the global prostate limits as the country records 200 cases out of every 100,000 men as against 170 world-wide, a survey by the Korle -Bu Teaching Hospital revealed(GNA - August, 07, 2007). This study aims to look at the impact of alternative medicine on Ghanaian men of African descent diagnosed with prostate cancer. This research study is in two forms, firstly an observational study will be used to assess Ghanaian men diagnosed with Prostate cancer and the use of traditional medicinal plant call croton membranaceus to ascertain its anti cancer efficacy. Croton membranaceus root extract marketed as URO 500 at Center For Plant Medicine Research in Ghana (Mampong , Akuapem) 10mg per capsule will be given to about 30 patient diagnosed with Prostate Cancer at the experimental site , De Men’s Clinic & Prostate Research Lab in Dodowa, Akoto House for an observational study to be conducted and cohort for this important research will report after three month of treatment after which their PSA will be assess again as the PSA is the best marker in terms of the diseases monitoring or progressing.
Secondly, an extensive research using online search engines to conduct a literature review, summarizing the body of evidence on impact of alternative medicine and prostate cancer use in men of African descent to date will be use for this important second phase of the study.
Results will be analyzed using the PSA at the stage at diagnosis and after treatment with the croton membranous. The International Prostate Symptoms score (IPSS) and the international Index of Erectile Function (IIEF) questionnaire will also be assessing before and after. Abdominopelvic Scan using Sonoscape A6 with full bladder to enable acoustic widow to assess prostate Volume before and after will also be access.
Evolving recommendations in prostate cancer screeningsummer elmorshidy
Prostate cancer screening recommendations have evolved as more evidence has emerged. Early approaches recommended annual PSA screening for all men over 50, but two large trials had conflicting results. One found no mortality benefit, while the other found a 21% reduction in men aged 55-69. However, significant overdiagnosis and harms were recognized, including false positives in 75% of biopsied men. Current guidelines recommend shared decision making for screening in men 55-69 and against screening for other age groups. Improved tests are still needed to better distinguish indolent from aggressive cancers.
This document discusses cancer screening guidelines for several common cancers. It recommends screening for breast cancer with annual mammograms and clinical exams starting at age 40, and beginning earlier or including MRI for those at high risk. Cervical cancer screening should begin at age 21 with Pap tests every 3 years or co-testing with HPV every 5 years. Colorectal cancer screening options include colonoscopy every 10 years, sigmoidoscopy every 5 years, or annual fecal tests. Genetic screening is recommended for those with a family history suggesting inherited cancer risk. Lung cancer screening with low-dose CT is advised for high-risk smokers aged 55-74. Prostate cancer screening involves PSA testing and DRE for men aged 50-69
Bitsie, K. (2015). Cancer Risk and Cancer Screening in a Pacific Northwest TribeNatalie Chin
This study assessed cancer risk factors and screening in the Cow Creek Band of Umpqua Tribe in Oregon through a survey of 283 tribal members. Compared to non-Hispanic whites in Oregon, tribal members were more likely to be obese and current smokers but had similar or higher rates of cancer screening. Specifically, tribal members were more likely to have received fecal occult blood tests and clinical breast exams recently. While some risk factors were elevated, cancer screening rates were generally favorable and suggested the tribe's health programs were having a positive impact.
Rush Radiosurgery presents the American Cancer Society Facts and Figures 2013 annual report outlining the estimated numbers of new cancer cases and deaths in 2013 as well as current cancer incidence, mortality, and survival statistics and information on cancer symptoms, risk factors, early detection, and treatment.
Lung Cancer is the leading cause of cancer-related deaths in the United States. Learn more about lung tumors and how Louisville CyberKnife's noninvasive treatment may be right for you.
A brain tumor is an abnormal growth of cells within the brain or the central spinal canal that can be cancerous or benign. Learn more about brain tumors and how St. Louis CyberKnife's noninvasive treatment may work for you.
Louisville CyberKnife presents the American Cancer Society Facts and Figures 2014 annual report outlining the estimated numbers of new cancer cases and deaths in 2014 as well as current cancer incidence, mortality, and survival statistics and information on cancer symptoms, risk factors, early detection and treatment. Please call Louisville CyberKnife at (502) 217-8200 for more information.
Prostate cancer is among the leading causes of cancer death among American men, second only to lung cancer. Learn more about prostate cancer and how New Jersey CyberKnife's noninvasive treatment may work for you.
The document provides information about prostate cancer and treatment options from Oklahoma CyberKnife. It discusses that a prostate cancer diagnosis can be scary and lists risk factors like age, race, and diet. It describes symptoms of early-stage prostate cancer and methods of diagnosis like PSA tests and biopsies. The document outlines CyberKnife treatment for prostate cancer, including fiducial marker implantation, treatment in a body mold over 5 sessions, and post-treatment follow up. It provides resources for the Oklahoma CyberKnife center.
Louisville CyberKnife is part of the James Graham Brown Cancer Center, home of the first nationally accredited radiation oncology program in Louisville.
Prostate cancer is one of the most common cancers in American men. The document provides information on prostate cancer prevention and risk factors. It recommends learning about personal risk factors and taking steps to prevent prostate cancer such as eating a healthy diet, maintaining a healthy weight, getting regular exercise, and avoiding smoking.
Prostate cancer is among the leading causes of cancer death among American men, second only to lung cancer. Learn more about prostate cancer and how Oklahoma CyberKnife's noninvasive treatment may work for you by calling (918) 949-6676.
A brain tumor is an abnormal growth of cells within the brain or the central spinal canal that can be cancerous or benign. Learn more about brain tumors and how Louisville CyberKnife's noninvasive treatment may work for you by calling (502) 217-8200.
Honoring Cancer Survivors in Northwest Ohio- Know How To Keep Yourself Safe f...AvaWilson88
Each year in the US, about 71,000 men and 64,000 women are diagnosed with colorectal cancer. Explore here some hidden facts about cancer and it's survivor. Know here about the success stories of cancer survivors and their caregivers: https://bit.ly/2VTC4QP
Colon cancer is the second leading cause of cancer deaths in the US. Regular screening can reduce the risk of death from colon cancer by 33% as it allows early detection and removal of pre-cancerous polyps. Dr. Rajiv Datta of the Gertrude & Louis Feil Cancer Center specializes in colon cancer surgery using minimally invasive techniques when possible and advocates for regular screening colonoscopies. Follow-up care after treatment including physical exams, colonoscopies, and CEA blood tests is important to monitor for recurrence of colon cancer.
Early diagnosis and screening for cancer was discussed. The presentation covered background on early diagnosis, cancer screening programmes including bowel, breast and cervical screening, and safety netting practices. Barriers to bowel cancer screening uptake were reviewed, along with practical tips practices can implement to increase uptake such as providing staff training, displaying screening information, and using practice data to review uptake. Resources for practices from Cancer Research UK including audit tools, guidelines and patient information materials were also presented.
This document summarizes new technology and treatments for breast cancer and other health issues at Catholic Medical Center. For breast cancer, CMC is introducing SAVI SCOUT technology, which involves placing a mini reflector clip near the tumor up to a week before surgery to precisely guide its removal. This allows for a more relaxed surgical experience. For fecal incontinence, CMC offers sacral nerve stimulation using the InterStim device, which has helped over 70% of patients reduce accidental bowel movements by at least 50%. The document also profiles a patient with Barrett's esophagus who was treated with radiofrequency ablation at CMC.
Prostate cancer is among the leading causes of cancer death among American men, second only to lung cancer. Learn more about prostate cancer and how Philadelphia CyberKnife's noninvasive treatment may work for you.
LI2DAY has donated a total of $150,500 to South Nassau in support of its breast cancer screening, early detection/diagnosis, and follow-up treatment program for underserved and minority patients.
June is dedicated to raising awareness and prevention of the preventable health problems men face while encouraging men to seek regular medical advice and early treatment for disease or injury.
Similar to Prostate Cancer: CyberKnife® Treatment Overview (20)
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
1. 529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
2. September
is
Prostate
Cancer
Awareness
Month!
A
prostate
cancer
diagnosis
can
be
scary.
Learn
more
about
prostate
cancer
and
how
we
can
help.
Please
note:
We
encourage
consumers
to
thoroughly
review
and
understand
all
treatment
op8ons.
The
informa8on
presented
here
is
not
all-‐inclusive.
Rather,
it
represents
a
star8ng
point
to
learn
more
about
medical
condi8ons
and
treatment
op8ons.
There
is
no
subs,tute
for
consul,ng
a
medical
professional.
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
3. 529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
4. About
Prostate
Cancer
The
prostate
is
a
walnut-‐shaped
organ
in
a
man’s
lower
abdomen
that
controls
the
flow
of
urine
and
semen
through
the
penis.
Prostate
cancer
is
among
the
leading
causes
of
cancer
death
among
American
men,
second
only
to
lung
cancer.
Risk
factors:
There
is
no
single
cause
of
prostate
cancer,
though
there
are
several
known
risk
factors:
• Age
–
Risks
generally
increase
for
older
men.
• Race
–
African-‐American
men
have
a
higher
risk
for
unknown
reasons.
• NaBonality
–
Asian
men,
for
example,
have
a
lower
risk.
• Diet
–
Red
meat
and
dairy
products
tend
to
increase
risk.
Several
studies
suggest
that
some
dietary
supplements
like
vitamin
E
and
lycopene
may
reduce
risk.
• Lack
of
exercise
• Family
history
of
prostate
cancer
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
5. • Early-‐stage
prostate
cancer
usually
has
no
symptoms.
Older
men
may
experience
frequent
urinaHon,
though
it’s
likely
due
to
an
enlarged
prostate
in
a
condiHon
known
as
benign
prostaHc
hypertrophy,
or
BPH.
Pain
or
bleeding
is
not
commonly
associated
with
early
stages.
• Prostate
cancer
is
suspected
if
men
have
an
elevated
level
of
a
substance
in
the
bloodstream
known
as
prostate
specific
anHgen
(PSA),
or
if
they
have
an
abnormality
like
a
nodule
found
during
a
digital
rectal
examinaHon.
A
prostate
cancer
diagnosis
is
confirmed,
however,
only
through
biopsy.
• Urologists
usually
perform
biopsies
as
an
outpaHent
procedure.
An
ultrasound
probe
is
used
to
guide
a
needle
that
removes
10
to
12
small
Hssue
samples
from
different
parts
of
the
prostate
gland.
SomeHmes,
addiHonal
diagnosHc
tests
like
a
bone
scan,
CT
or
MRI
are
performed,
depending
on
the
specific
diagnosis.
What
are
symptoms
of
prostate
cancer?
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
6. 529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
7. How
does
CyberKnife
treat
prostate
cancer?
Prior
to
stereotacHc
body
radiosurgery
treatment
with
CyberKnife,
small
Hssue
markers
known
as
fiducials
are
implanted
in
the
prostate
to
help
the
CyberKnife
pinpoint
the
tumor
locaHon
throughout
each
treatment,
so
the
radiaHon
beams
can
be
locked
on
the
tumor.
About
a
week
later,
paHents
are
fiWed
with
a
custom
body
mold
of
soX
material
that
they
lie
on
during
treatments.
The
fiYng
process
is
painless.
The
treatment
process
includes:
I. ConsultaHon
appointment
II. Pretreatment
procedures
III. CyberKnife
treatment
IV. Follow-‐up
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
8. ConsultaBon
and
Pretreatment
Procedures
Louisville
CyberKnife
physicians,
therapists
and
nurses
are
focused
on
your
individualized
treatment
plan:
• You
will
meet
a
Louisville
CyberKnife
radiaHon
oncologist
to
decide
if
CyberKnife
treatment
is
appropriate
for
your
diagnosis.
• Your
CyberKnife
team
will
decide
which
pretreatment
procedures
you
may
need
to
help
develop
your
treatment
plan.
These
could
include
a
CT
scan,
an
MRI,
laboratory
studies
or
Hssue
markers.
• The
data
from
your
pretreatment
procedures
will
be
used
by
the
CyberKnife
team
to
determine
the
exact
size,
shape
and
locaHon
of
your
tumor.
• This
informaHon
will
indicate
the
size
of
the
area
being
treated
with
radiaHon,
the
radiaHon
dose
and
criHcal
structures
where
radiaHon
exposure
should
be
minimized.
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
9. CyberKnife
Treatment
Typically
treatment
is
completed
within
five
sessions.
On
the
day
of
your
treatment:
1. A
therapist
will
help
you
onto
the
treatment
table
and
fit
the
body
mold.
PaHents
are
observed
throughout
the
treatment
on
closed-‐
circuit
television,
and
they
can
pause
treatment
at
any
Hme
by
waving
or
speaking
to
the
technicians.
2. While
the
CyberKnife’s
advanced
tracking
system
accounts
for
movements
like
breathing,
you’re
asked
to
lie
sHll
during
treatments.
The
system
periodically
takes
x-‐ray
images
and
compares
them
to
the
CT
scan
data
to
make
sure
the
radiaHon
beam
is
locked
on
the
tumor.
3. PaHents
can
usually
return
to
their
normal
rouHnes
once
the
treatment
is
complete.
FOR
YOUR
INFORMATION
• Treatment
procedures
take
about
30
–
90
minutes,
depending
on
the
complexity
of
your
tumor.
• PaHents
are
asked
to
wear
comfortable
clothing
during
CyberKnife
treatments.
Jewelry
is
acceptable
unless
it
is
close
to
the
area
being
treated.
• Feel
free
to
bring
an
iPod®
or
your
favorite
music
CDs
with
you
on
the
day
of
your
treatment,
and
we
will
play
them
for
you
during
the
procedure.
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
10. AddiBonal
Resources
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
11. Our Center
Louisville
CyberKnife
is
part
of
the
renowned
James
Graham
Brown
Cancer
Center,
home
of
the
first
naHonally
accredited
radiaHon
oncology
program
in
Louisville.
The
Brown
Cancer
Center
is
a
partner
of
KentuckyOne
Health,
an
integrated
comprehensive
health
system
offering
nearly
200
locaHons
across
the
state
of
Kentucky
and
southern
Indiana.
If
you
or
a
loved
one
is
diagnosed
with
prostate
cancer,
contact
Louisville
CyberKnife
to
schedule
a
consultaHon
with
our
physicians
to
determine
the
best
next
step
for
your
treatment
needs.
Connect
with
us
529 S. Jackson Street, Louisville, KY 40202 (502) 217-8200 www.louisvilleck.com
Medical
Director:
Shiao
Woo,
M.D.,
M.B.B.S.
F.A.C.R.
RadiaBon
Oncologist:
Moataz
El-‐Ghamry,
M.D.
RadiaBon
Oncologist:
Anthony
E.
Dragun,
M.D.
RadiaBon
Oncologist:
Neal
E.
Dunlap,
M.D.
CyberKnife
Nurse
Manager:
Anna
Murphy,
RN